# Revance Therapeutics, Inc. clinical trials: 29 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 29 trials with Revance Therapeutics, Inc. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Revance Therapeutics, Inc.: 29 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/revance-therapeutics-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 29
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 29, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| May 13, 2024 | NCT06411002 | Phase 2a Study of DaxibotulinumtoxinA-lanm for Injection in Dynamic Forehead Lines and Glabellar Lines | Revance Therapeutics, Inc. | Phase 2 | Completed | Glabellar Frown Lines | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06411002) |
| April 15, 2021 | NCT04846530 | Teosyal RHA® Histology and Intradermal Implantation Evaluation Study | Revance Therapeutics, Inc. | Observational | Unknown | Histology | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04846530) |
| February 6, 2020 | NCT04259086 | Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines | Revance Therapeutics, Inc. | Phase 2 | Completed | Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines) | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04259086) |
| April 10, 2019 | NCT03911102 | Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe... | Revance Therapeutics, Inc. | Phase 2 | Completed | Lateral Canthal Lines | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03911102) |
| January 31, 2019 | NCT03825315 | DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis | Revance Therapeutics, Inc. | Phase 2 | Completed | Plantar Fasciitis | 155 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03825315) |
| January 29, 2019 | NCT03821402 | Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb Spasticity | Revance Therapeutics, Inc. | Phase 2 | Completed | Upper Limb Spasticity | 83 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03821402) |
| December 26, 2018 | NCT03786770 | Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis) | Revance Therapeutics, Inc. | Phase 2 | Completed | Frown Lines | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03786770) |
| August 6, 2018 | NCT03617367 | Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia... | Revance Therapeutics, Inc. | Phase 3 | Completed | Cervical Dystonia | 357 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03617367) |
| August 1, 2018 | NCT03608397 | Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1) | Revance Therapeutics, Inc. | Phase 3 | Completed | Cervical Dystonia | 301 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03608397) |
| May 2, 2017 | NCT03137407 | Phase 2 DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis | Revance Therapeutics, Inc. | Phase 2 | Completed | Plantar Fasciitis | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03137407) |
| January 9, 2017 | NCT03014635 | Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines | Revance Therapeutics, Inc. | Phase 3 | Completed | Glabellar Frown Lines | 306 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03014635) |
| January 9, 2017 | NCT03014622 | Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines | Revance Therapeutics, Inc. | Phase 3 | Completed | Glabellar Frown Lines | 303 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03014622) |
| December 28, 2016 | NCT03004248 | Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines | Revance Therapeutics, Inc. | Phase 3 | Completed | Glabellar Frown Lines | 2,691 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03004248) |
| November 25, 2016 | NCT02973269 | DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis | Revance Therapeutics, Inc. | Phase 2 | Terminated | Plantar Fasciitis | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02973269) |
| March 11, 2016 | NCT02706795 | Dose-escalating Safety and Preliminary Efficacy of DaxibotulinumtoxinA for Injection in Cervical Dystonia | Revance Therapeutics, Inc. | Phase 2 | Completed | Torticollis (Spasmodic) | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02706795) |
| October 20, 2015 | NCT02580370 | Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines | Revance Therapeutics, Inc. | Phase 3 | Completed | Skin Aging | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02580370) |
| October 1, 2015 | NCT02565732 | Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis | Revance Therapeutics, Inc. | Phase 2 | Completed | Hyperhidrosis | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02565732) |
| November 27, 2014 | NCT02303002 | Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines | Revance Therapeutics, Inc. | Phase 2 | Completed | Glabellar Frown Lines | 268 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02303002) |
| September 12, 2013 | NCT01940991 | Efficacy and Safety of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines | Revance Therapeutics, Inc. | Phase 2 | Completed | Skin Aging | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01940991) |
| March 26, 2013 | NCT01818076 | Open Label Study to Assess Long-term Safety of Repeat Administration of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines | Revance Therapeutics, Inc. | Phase 3 | Terminated | Skin Aging | 311 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01818076) |
| January 28, 2013 | NCT01776606 | Efficacy and Safety Study of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines | Revance Therapeutics, Inc. | Phase 3 | Completed | Skin Aging | 247 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01776606) |
| May 17, 2010 | NCT01124565 | Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults | Revance Therapeutics, Inc. | Phase 2 | Completed | Lateral Canthal Lines, Crow's Feet, Facial Wrinkles | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01124565) |
| May 17, 2010 | NCT01124552 | A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults | Revance Therapeutics, Inc. | Phase 2 | Completed | Lateral Canthal Lines, Crow's Feet, Facial Wrinkles | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01124552) |
| February 8, 2010 | NCT01064518 | Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults | Revance Therapeutics, Inc. | Phase 2 | Completed | Lateral Canthal Lines, Crow's Feet, Facial Wrinkles | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01064518) |
| August 31, 2009 | NCT00968942 | Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines | Revance Therapeutics, Inc. | Phase 2 | Completed | Lateral Canthal Lines, Crow's Feet, Facial Wrinkles | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00968942) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 2 | 20 |
| Phase 3 | 8 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 26 |
| Terminated | 2 |
| Unknown | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Torticollis | 3 |
| Fasciitis, Plantar | 3 |
| Hyperhidrosis | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Syrian restaurants in the United States](https://specstream.ai/data/businesses/syrian-restaurants/united-states)
- [Irish pubs in the United States](https://specstream.ai/data/businesses/irish-pubs/united-states)
- [Burmese restaurants in the United States](https://specstream.ai/data/businesses/burmese-restaurants/united-states)
- [Rubber and plastics manufacturers in the United States](https://specstream.ai/data/businesses/rubber-and-plastics-manufacturers/united-states)
- [Halal restaurants in the United States](https://specstream.ai/data/businesses/halal-restaurants/united-states)
- [B2B medical support companies in the United States](https://specstream.ai/data/businesses/b2b-medical-support-companies/united-states)
